SCHEMBL5227927

SCHEMBL5227927

Clc1ccc2c(c1)-c1[nH]cnc1-c1ccccc1O2

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.47
IDO1 P14902 3/20 0.44
DRD2 P14416 5/20 0.41
DRD4 P21917 5/20 0.41
CYP3A4 P08684 4/20 0.41
HRH2 P25021 3/20 0.41
HRH1 P35367 3/20 0.41
ADRA2A P08913 3/20 0.41
CYP1A2 P05177 3/20 0.41
CYP2D6 P10635 3/20 0.41
ALDH1A1 P00352 2/20 0.41
ADRB2 P07550 2/20 0.41
CHRM2 P08172 2/20 0.41
CHRM4 P08173 2/20 0.41
HTR1A P08908 2/20 0.41
CHRM5 P08912 2/20 0.41
ADORA3 P0DMS8 2/20 0.41
CHRM1 P11229 2/20 0.41
ADRA2B P18089 2/20 0.41
ADRA2C P18825 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4697157 0.94 MAPK1 (0.47) MAPK1IDO1DRD2DRD4CYP3A4
SCHEMBL4694417 0.85 ALDH1A1 (0.49) MAPK1IDO1CYP3A4CYP1A2CYP2D6
SCHEMBL5228795 0.76 MAPK1 (0.48) MAPK1DRD2DRD4CYP3A4HRH2
SCHEMBL30912194 0.75 MAPK1 (0.50) MAPK1DRD2DRD4CYP3A4HRH2
SCHEMBL4695701 0.74 IDO1 (0.44) IDO1DRD2DRD4CYP3A4HRH1
SCHEMBL4499503 0.72 MAPK1 (0.48) MAPK1DRD2DRD4CYP3A4HRH2
SCHEMBL19537683 0.72 MAPK1 (0.57) MAPK1DRD2DRD4CYP3A4HRH2
SCHEMBL4080406 0.70 DPP4 (0.46) IDO1CYP1A2ALDH1A1TP53MAPT
SCHEMBL8105110 0.70 ALDH1A1 (0.50) IDO1CYP3A4ALDH1A1HTR7TP53
SCHEMBL4491978 0.70 MAPK1 (0.48) MAPK1DRD2DRD4CYP3A4HRH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1684749-B1 USE OF 1,3-DIAZA-DIBENZO[e,h] AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS GLAXOSMITHKLINE ZAGREB (HR) 2007-09-05 EP disclosed